Valentis (VLTS) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Valentis (VLTS)

An SI Board Since April 1999

Posts	SubjectMarks	Bans	Symbol
81	15	0	VLTS

Emcee: Mike McFarland	Type: Unmoderated

Introduction Market Data Compact

Took this off the company website, seems like
the best way to kick off the new thread.

MEGABIOS AND GeneMedicine COMPLETE MERGER
COMBINED COMPANY TO BE NAMED VALENTIS, INC.

Burlingame, Calif., Match 19, 1999 -- Megabios Corp. (NASDAQ:MBIO)
and GeneMedicine Inc. (NASDAQ:GMED) announced today the completion
of the merger of the two companies. The combined company intends
to operate under the new name of Valentis, Inc. in the near future.

"The merger of Megabios and GeneMedicine creates a new company with
a stronger and broader technology platform, outstanding partners and
a diversified portfolio of products in clinical and preclinical
development," said Benjamin F. McGraw, III, Chairman, President and
CEO of Megabios. "We believe the combination of these companies will
result in Valentis emerging as the obvious partnering choice for
biotechnology and pharmaceutical companies pursuing plasmid-based
gene medicines."

The technology focus of Valentis (the combination of Megabios and
GeneMedicine) will continue to be gene delivery and its applications
in the development of gene medicines for diseases with high unmet
medical need. Valentis has seven products in clinical development.
In oncology, the Company is developing interleukin-2 (IL-2) and alpha
interferon (INF-a) in a partnership with Hoffman La Roche and a
combination of IL-2 and superantigen-B (IL-2/SEB) under a grant
from the National Cancer Institute. In the cardiovascular area,
the Company has a vascular endothelial growth factor (VEGF) in
two physician-sponsored phase II trials for peripheral vascular
disease and coronary artery disease. In the pulmonary field, Valentis
has completed a phase I/II trial of alpha-1 antitrypsin (AAT), and
has a cystic fibrosis product in clinical development with Glaxo
Wellcome.

The Company also has a number of products in preclinical development
including IL-12 and cytokine combinations for cancer applications
with Roche and partnerships with Eli Lilly for the development
of BRCA-1 for breast and ovarian cancer, Heska for animal health
products and Merck for the Company's GeneSwitch™ technology.

Valentis, through its partnership with DSM Biologics, offers a
complete solution for manufacturing ultra-pure plasmids from
laboratory scale through commercial-level production. This
partnership is currently marketing the manufacture of plasmid
DNA to the biotechnology and pharmaceutical industries. This
creates near term revenue opportunities in advance of the launch
of commercial gene medicines.

Megabios is a leader in the field of gene medicines. The Company
develops proprietary gene delivery systems and applies its preclinical
and early clinical development expertise to create gene-based
products. The Company's core technologies include multiple gene
delivery and gene expression systems, each able to be applied to
specific clinical targets. These technologies are covered by a
broad patent portfolio that includes issued U.S. and European claims
for the use of any cationic lipid combined with DNA and administered
by injection or inhalation, the most common routes of administration
in gene therapy. The Company's commercial strategy is to enter into
corporate partnerships for full-scale clinical development and
marketing and sales of products. The company is in the process of
establishing a new website at www.valentis.com. Additional information
can be found at www.megabios.com and www.gmed.com.
(snip)

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
81	Valentis and Schering A.G. Enter Multi-Product Collaboration BURLINGAME, Calif.	nigel bates	-	12/20/2002
80	Valentis Extends Tender Offer to October 15, 2002 BURLINGAME, Calif., Aug. 30	SemiBull	-	9/2/2002
79	Valentis Receives Nasdaq Delisting Notice and Plans Appeal BURLINGAME, Calif.,	SemiBull	-	8/27/2002
78	Mike, I am presently only tracking VLTS. Consequently, I tend to assume your p	SemiBull	-	7/14/2002
77	Semi--do you have any opinion on all this, I bog down when I read this stuff, in	Mike McFarland	-	7/11/2002
76	Valentis Extends Tender Offer to September 3, 2002 BURLINGAME, Calif., July 3 /	SemiBull	-	7/4/2002
75	Valentis Announces Extension of Tender Offer to July 8, 2002 BURLINGAME, Calif.	SemiBull	-	6/5/2002
74	Westfield rates Valentis "speculative buy" NEW YORK, June 4 (Reuters)	SemiBull	-	6/4/2002
73	Valentis Announces the Issuance of Two Broad Patents BURLINGAME, Calif., May 28	SemiBull	-	5/28/2002
72	Valentis Licenses GeneSwitch(R) Gene Regulation Technology to Medigene A.G. BUR	SemiBull	-	5/20/2002
71	Valentis Announces Offer to Purchase for Cash Its Series a Preferred Stock BURL	SemiBull	-	5/12/2002
70	Valentis Announces Third Quarter Fiscal 2002 Financial Results BURLINGAME, Cali	SemiBull	-	5/12/2002
69	Valentis Announces Issuance of Pegylated Liposomes Patent in Europe, Initiation	SemiBull	-	4/24/2002
68	>>BURLINGAME, Calif., Jan. 15 /PRNewswire-FirstCall/ -- Valentis, Inc. (Na	tuck	-	1/15/2002
67	Valentis Enters Cross License Agreement With Genzyme BURLINGAME, Calif., Jan. 9	SemiBull	-	1/9/2002
66	psbiofund.com SAB is not given, but found this: Dr. Marc E. Lippman serves as	Mike McFarland	-	12/28/2001
65	Thu 5:43pm VLTS Perseus-Soros fund takes 5 pct stake in Valentis - Reuters Secur	gao seng	-	12/27/2001
64	Sure hope they have a portfolio of therapies undergoing differing stages of FDA	SemiBull	-	12/3/2001
63	Ouch for shareholders: >>BURLINGAME, Calif., Dec 3, 2001 /PRNewswire via	tuck	-	12/3/2001
62	Valentis Licenses Electroporation Technology From Genetronics BURLINGAME, Calif.	SemiBull	-	11/29/2001
61	>>BURLINGAME, Calif., Nov. 14 /PRNewswire/ -- Valentis, Inc. (Nasdaq: VLTS	tuck	-	11/14/2001
60	>>BURLINGAME, Calif., Aug. 1 /PRNewswire/ -- Valentis, Inc. (Nasdaq: VLTS	tuck	-	8/1/2001
59	chit chat OT* Well, I don't anymore own shares of Valentis. messages.yaho	Mike McFarland	-	7/6/2001
58	Missed this abstract --ASGT No. 464 Adenovirus Vectors Modified with Polyethyl	Mike McFarland	-	6/21/2001
57	ViraMASC (I'm getting awfully forgetful, so just catching up on some filing	Mike McFarland	-	6/21/2001

Go to reply# or date (mm/dd/yy):